Amsterdam, 1100 DA
312 056 67394
Amsterdam Molecular Therapeutics engages in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB.
Amsterdam Molecular Therapeutics Holding N.V. was acquired by uniQure Biopharma BV on February 17, 2012.
Join Mergr to view all 119 acquisitions of life science companies in 2012, including 19 acquisitions by private equity firms, and 100 by strategics.
Out of 60 sectors in the Mergr database, life science ranked 19 in number of deals in 2012. The largest life science acquisition in 2012 was Amylin Pharmaceuticals - which was acquired by Bristol-Myers Squibb for $5.3B.
Join Mergr to view this profile - and discover more life science acquisitions of companies like Amsterdam Molecular Therapeutics Holding N.V..
No obligation. Cancel anytime.